mRNA-1010 Vaccine for Flu
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new flu vaccine called mRNA-1010 to see if it is safe and effective for people who need flu shots. The new vaccine uses a small piece of genetic material to help the body recognize and fight the flu virus.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on systemic immunosuppressants or certain immune therapies, you may need to stop them before joining the trial. It's best to discuss your specific medications with the trial team.
Is the mRNA-1010 vaccine for flu generally safe for humans?
How is the mRNA-1010 vaccine different from other flu vaccines?
The mRNA-1010 vaccine is unique because it uses messenger RNA (mRNA) technology to stimulate an immune response against the flu, potentially offering a faster and more adaptable production process compared to traditional flu vaccines. It has shown to elicit higher immune responses for certain flu strains and is designed to be a quadrivalent vaccine, targeting multiple strains of the virus.678910
Are You a Good Fit for This Trial?
This trial is for healthy adults who can become pregnant but are not currently, using contraception or abstaining from pregnancy-causing activities. They must have a BMI of 18-<40 kg/m^2 (Part A only), no acute illness/fever before vaccination, and no history of severe allergies to mRNA or flu vaccines.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of the assigned vaccine by intramuscular injection on Day 1
Follow-up
Participants are monitored for safety and immunogenicity, with seroresponse measured at Day 29
Extended Follow-up
Participants are monitored for long-term immunogenicity with seroresponse measured at Days 57, 121, and 181
What Are the Treatments Tested in This Trial?
Interventions
- Adjuvanted Quadrivalent Influenza Vaccine
- Egg-based Quadrivalent Influenza Vaccine
- Inactivated Influenza Vaccine
- mRNA-1010
Find a Clinic Near You
Who Is Running the Clinical Trial?
ModernaTX, Inc.
Lead Sponsor
Dr. Stephen Hoge
ModernaTX, Inc.
Chief Medical Officer
MD from Harvard Medical School
Stéphane Bancel
ModernaTX, Inc.
Chief Executive Officer since 2011
MBA from Harvard Business School, MSc in Engineering from École Centrale Paris